TREM2 and autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation: Indeed, both inhibitors and activators/potentiators would provide as useful therapeutics in different diseases (from APLAID to AD, see chapter: “The spectrum of clinical phenotypes manifested by TREM2 and PLCG2 polymorphisms”).